TY  - JOUR
AU  - Brzaković, Branka
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Prostran, Milica
AU  - Martinović, Žarko J.
AU  - Pokrajac, Milena
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2183
AB  - The purpose of the study was to examine and describe adjunctive lamotrigine (LTG) pharmacokinetics in paediatric and young adult patients using a nonlinear mixed effects modelling (NONMEM) approach. The study included 53 patients (age range 3-35 years) who were concomitantly treated with carbamazepine (CBZ) and/or valproic acid (VPA). A total of 70 blood samples corresponding to trough levels were available for analysis. Data were modelled, and the final model was evaluated using NONMEM and auxiliary software tools. The final LTG population model included the effects of concomitant drugs and patient's weight (WT) which stratified the population into three groups: a parts per thousand currency sign25 kg, > 25 to  lt  60 kg and a parts per thousand yen60 kg. Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing a parts per thousand currency sign25 kg, > 25 to  lt  60 kg or a parts per thousand yen60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively. If a patient was concomitantly treated with CBZ + VPA, the CL/F decreased on average by 69.5 % relative to LTG + CBZ co-therapy. VPA was found to decrease the LTG CL/F by 87.6 % compared to co-therapy with only CBZ. The LTG population pharmacokinetic model developed in this study may be a reliable method for individualising the LTG dosing regimen in paediatric and young adult patients on combination therapy during therapeutic drug monitoring.
PB  - Springer Heidelberg, Heidelberg
T2  - European Journal of Clinical Pharmacology
T1  - Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach
VL  - 70
IS  - 2
SP  - 179
EP  - 185
DO  - 10.1007/s00228-013-1606-5
ER  - 

@article{
author = "Brzaković, Branka and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Miljković, Branislava and Prostran, Milica and Martinović, Žarko J. and Pokrajac, Milena",
year = "2014",
abstract = "The purpose of the study was to examine and describe adjunctive lamotrigine (LTG) pharmacokinetics in paediatric and young adult patients using a nonlinear mixed effects modelling (NONMEM) approach. The study included 53 patients (age range 3-35 years) who were concomitantly treated with carbamazepine (CBZ) and/or valproic acid (VPA). A total of 70 blood samples corresponding to trough levels were available for analysis. Data were modelled, and the final model was evaluated using NONMEM and auxiliary software tools. The final LTG population model included the effects of concomitant drugs and patient's weight (WT) which stratified the population into three groups: a parts per thousand currency sign25 kg, > 25 to  lt  60 kg and a parts per thousand yen60 kg. Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing a parts per thousand currency sign25 kg, > 25 to  lt  60 kg or a parts per thousand yen60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively. If a patient was concomitantly treated with CBZ + VPA, the CL/F decreased on average by 69.5 % relative to LTG + CBZ co-therapy. VPA was found to decrease the LTG CL/F by 87.6 % compared to co-therapy with only CBZ. The LTG population pharmacokinetic model developed in this study may be a reliable method for individualising the LTG dosing regimen in paediatric and young adult patients on combination therapy during therapeutic drug monitoring.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "European Journal of Clinical Pharmacology",
title = "Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach",
volume = "70",
number = "2",
pages = "179-185",
doi = "10.1007/s00228-013-1606-5"
}

Brzaković, B., Vučićević, K., Vezmar-Kovačević, S., Miljković, B., Prostran, M., Martinović, Ž. J.,& Pokrajac, M.. (2014). Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach. in European Journal of Clinical Pharmacology
Springer Heidelberg, Heidelberg., 70(2), 179-185.
https://doi.org/10.1007/s00228-013-1606-5

Brzaković B, Vučićević K, Vezmar-Kovačević S, Miljković B, Prostran M, Martinović ŽJ, Pokrajac M. Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach. in European Journal of Clinical Pharmacology. 2014;70(2):179-185.
doi:10.1007/s00228-013-1606-5 .

Brzaković, Branka, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Miljković, Branislava, Prostran, Milica, Martinović, Žarko J., Pokrajac, Milena, "Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients-nonlinear mixed effects modelling approach" in European Journal of Clinical Pharmacology, 70, no. 2 (2014):179-185,
https://doi.org/10.1007/s00228-013-1606-5 . .

TY  - JOUR
AU  - Kostić, Vladimir
AU  - Džoljić, Eleonora
AU  - Todorović, Zoran
AU  - Mijajlović, Milija
AU  - Svetel, Marina
AU  - Stefanova, Elka
AU  - Dragašević, Nataša
AU  - Petrović, Igor
AU  - Milošević, Milenko
AU  - Kovačević, Ivan
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Prostran, Milica
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1825
AB  - Background/Aim. Selective serotonin reuptake inhibitors are the most commonly chosen antidepressants in patients with Parkinson's disease (PD). The aim of our study was to assess the influence of fluoxetine (Flu) on motor functions in patients with PD. Methods. In this prospective, controlled, open-label study, 18 patients with PD and mild depression [(10 ≤ Hamilton Rating Scale for Depression (HDRS) ≤ 23)] without dementia [(25 ≤ Mini-Mental State Examination (MMSE)] were treated with Flu. Both single and repeated dose effects of Flu were assessed on days 1-80. Plasma concentrations of Flu and norfluoxetine (NORFlu) were correlated with the results of selected motor function performance scores: The Unified Parkinsons Disease Rating Score (UPDRS), Finger Tapping Test (FTT) and Purdue Pegboard Test (PPT). Severity of PD, depression and dementia were evaluated using standard tests [(Hoehn and Yahr stages (HY), activity of daily living (ADL), UPDRS, HDRS, MMSE)]. Results. Steady-state for Flu/NORFlu was reached after 18 days of treatment. Such a plateau correlated with significant improvements in both scores of depression and Parkinson's disability (HDRS, UPDRS and ADL, respectively). In addition, FTT and PPT scores also increased until day 18, with further slight fluctuations around the plateau. Optimal motor performances correlated with Flu concentrations of approximately 60-110 μg/L. Conclusion. Flu (20 mg/day) significantly reduced depression in PD patients while it did not impair their motor performances. Because substantial placebo effects may arise in studies of PD and depression, large, prospective, randomized, placebo-controlled clinical trials are warranted.
AB  - Uvod/Cilj. Selektivni inhibitori ponovnog preuzimanja serotonina su antidepresivi koji se najčešće koriste u lečenju obolelih od Parkinsonove bolesti (PB). Cilj ovog istraživanja bio je da se proceni uticaj fluoksetina (Flu) na motorne funkcije bolesnika sa PB. Metode. U ovom prospektivnom, kontrolisanom, otvorenom kliničkom ispitivanju, 18 bolesnika sa PB i blagom depresijom [10 ≤ Hamiltonova skala za depresiju (10 ≤ HDRS) ≤ 23)], bez demencije [(25 ≤ Mini mental test (MMSE)] lečeni su primenom Flu. Procenjivana su dejstva kako pojedinačne, tako i ponovljene doze Flu od prvog do osamdesetog dana. Plazma koncentracije Flu i norfluoksetina (NORFlu) korelisane su sa rezultatima odeđenih testova za motorne funkcije: skala za procenu težine PB (UPDRS), test spretnosti kucanja (FTT) i Purdue pegboard Test PPT). Izraženost PD, depresije i demencije procenjivane su korišćenjem standardnih testova [(test dnevnih aktivnosti (ADL), Hoehn.-Yahr. stadijumi (HJ), HDRS, MMSE)]. Rezultati. Ravnotežno stanje za Flu/NORFlu postignuto je 18. dana lečenja. Takav plato u koncentraciji Flu/NORFlu bio je praćen značajnim poboljšanjem rezultata, kako testova za depresiju, tako i za izraženost PB (HDRS, UPDRS i ADL, sledstveno). Dodatno, rezultati FTT-a i PPT-a bili su u porastu do 18. dana, sa blagim fluktuacijama oko platoa. Optimalna motorna postignuća zabeležena su pri koncentraciji Flu od oko 60-110 μg/L. Zaključak. Flu (20 mg/dan) značajno redukuje depresiju kod bolesnika sa PB i ne remeti motorne funkcije. S obzirom na mogući placebo efekat u istraživanjima sa PB i depresijom, neophodna su obimnija, prospektivna, randomizovana, placebo- kontrolisana klinička ispitivanja.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine
T1  - Fluoksetin ne remeti motornu funkciju kod bolesnika sa Parkinsonovom bolešću - korelacija raspoloženja i motorne funkcije sa koncentracijom fluoksetina/norfluoksetina u plazmi
VL  - 69
IS  - 12
SP  - 1067
EP  - 1075
DO  - 10.2298/VSP111114028K
ER  - 

@article{
author = "Kostić, Vladimir and Džoljić, Eleonora and Todorović, Zoran and Mijajlović, Milija and Svetel, Marina and Stefanova, Elka and Dragašević, Nataša and Petrović, Igor and Milošević, Milenko and Kovačević, Ivan and Miljković, Branislava and Pokrajac, Milena and Prostran, Milica",
year = "2012",
abstract = "Background/Aim. Selective serotonin reuptake inhibitors are the most commonly chosen antidepressants in patients with Parkinson's disease (PD). The aim of our study was to assess the influence of fluoxetine (Flu) on motor functions in patients with PD. Methods. In this prospective, controlled, open-label study, 18 patients with PD and mild depression [(10 ≤ Hamilton Rating Scale for Depression (HDRS) ≤ 23)] without dementia [(25 ≤ Mini-Mental State Examination (MMSE)] were treated with Flu. Both single and repeated dose effects of Flu were assessed on days 1-80. Plasma concentrations of Flu and norfluoxetine (NORFlu) were correlated with the results of selected motor function performance scores: The Unified Parkinsons Disease Rating Score (UPDRS), Finger Tapping Test (FTT) and Purdue Pegboard Test (PPT). Severity of PD, depression and dementia were evaluated using standard tests [(Hoehn and Yahr stages (HY), activity of daily living (ADL), UPDRS, HDRS, MMSE)]. Results. Steady-state for Flu/NORFlu was reached after 18 days of treatment. Such a plateau correlated with significant improvements in both scores of depression and Parkinson's disability (HDRS, UPDRS and ADL, respectively). In addition, FTT and PPT scores also increased until day 18, with further slight fluctuations around the plateau. Optimal motor performances correlated with Flu concentrations of approximately 60-110 μg/L. Conclusion. Flu (20 mg/day) significantly reduced depression in PD patients while it did not impair their motor performances. Because substantial placebo effects may arise in studies of PD and depression, large, prospective, randomized, placebo-controlled clinical trials are warranted., Uvod/Cilj. Selektivni inhibitori ponovnog preuzimanja serotonina su antidepresivi koji se najčešće koriste u lečenju obolelih od Parkinsonove bolesti (PB). Cilj ovog istraživanja bio je da se proceni uticaj fluoksetina (Flu) na motorne funkcije bolesnika sa PB. Metode. U ovom prospektivnom, kontrolisanom, otvorenom kliničkom ispitivanju, 18 bolesnika sa PB i blagom depresijom [10 ≤ Hamiltonova skala za depresiju (10 ≤ HDRS) ≤ 23)], bez demencije [(25 ≤ Mini mental test (MMSE)] lečeni su primenom Flu. Procenjivana su dejstva kako pojedinačne, tako i ponovljene doze Flu od prvog do osamdesetog dana. Plazma koncentracije Flu i norfluoksetina (NORFlu) korelisane su sa rezultatima odeđenih testova za motorne funkcije: skala za procenu težine PB (UPDRS), test spretnosti kucanja (FTT) i Purdue pegboard Test PPT). Izraženost PD, depresije i demencije procenjivane su korišćenjem standardnih testova [(test dnevnih aktivnosti (ADL), Hoehn.-Yahr. stadijumi (HJ), HDRS, MMSE)]. Rezultati. Ravnotežno stanje za Flu/NORFlu postignuto je 18. dana lečenja. Takav plato u koncentraciji Flu/NORFlu bio je praćen značajnim poboljšanjem rezultata, kako testova za depresiju, tako i za izraženost PB (HDRS, UPDRS i ADL, sledstveno). Dodatno, rezultati FTT-a i PPT-a bili su u porastu do 18. dana, sa blagim fluktuacijama oko platoa. Optimalna motorna postignuća zabeležena su pri koncentraciji Flu od oko 60-110 μg/L. Zaključak. Flu (20 mg/dan) značajno redukuje depresiju kod bolesnika sa PB i ne remeti motorne funkcije. S obzirom na mogući placebo efekat u istraživanjima sa PB i depresijom, neophodna su obimnija, prospektivna, randomizovana, placebo- kontrolisana klinička ispitivanja.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine, Fluoksetin ne remeti motornu funkciju kod bolesnika sa Parkinsonovom bolešću - korelacija raspoloženja i motorne funkcije sa koncentracijom fluoksetina/norfluoksetina u plazmi",
volume = "69",
number = "12",
pages = "1067-1075",
doi = "10.2298/VSP111114028K"
}

Kostić, V., Džoljić, E., Todorović, Z., Mijajlović, M., Svetel, M., Stefanova, E., Dragašević, N., Petrović, I., Milošević, M., Kovačević, I., Miljković, B., Pokrajac, M.,& Prostran, M.. (2012). Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 69(12), 1067-1075.
https://doi.org/10.2298/VSP111114028K

Kostić V, Džoljić E, Todorović Z, Mijajlović M, Svetel M, Stefanova E, Dragašević N, Petrović I, Milošević M, Kovačević I, Miljković B, Pokrajac M, Prostran M. Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. in Vojnosanitetski pregled. 2012;69(12):1067-1075.
doi:10.2298/VSP111114028K .

Kostić, Vladimir, Džoljić, Eleonora, Todorović, Zoran, Mijajlović, Milija, Svetel, Marina, Stefanova, Elka, Dragašević, Nataša, Petrović, Igor, Milošević, Milenko, Kovačević, Ivan, Miljković, Branislava, Pokrajac, Milena, Prostran, Milica, "Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine" in Vojnosanitetski pregled, 69, no. 12 (2012):1067-1075,
https://doi.org/10.2298/VSP111114028K . .

TY  - JOUR
AU  - Brzaković, B. B.
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Martinović, Žarko J.
AU  - Pokrajac, Milena
AU  - Prostran, Milica
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1634
AB  - What is known and Objective: Lamotrigine metabolism may be substantially altered with concomitant administration of valproic acid and/or carbamazepine. Such alterations may require the adjustment of lamotrigine dose to ensure optimal treatment efficacy and safety. Methods: The extent of lamotrigine interactions was investigated dependent on age, gender, weight and dose of concomitant carbamazepine and/or valproic acid in 65 patients with epilepsy. Lamotrigine plasma steady-state oral clearance (CLss/F) and area under the curve (AUCss) were calculated from the dose of drug, average steady-state concentration (Css) and interval of administration. Multiple regression analysis was used for the identification and quantification of factors that influenced lamotrigine pharmacokinetics. Results and Discussion: Age and dose of carbamazepine and valproic acid had significant influence on lamotrigine CLss/F and AUCss. Carbamazepine was associated with a dose-dependent increase and valproic acid with a dose-dependent decrease of lamotrigine metabolism rate. The effect of carbamazepine was more pronounced. Younger patients were expected to metabolize lamotrigine more rapidly whereas overweight patients may be less susceptible to interactions. Gender had no influence on lamotrigine pharmacokinetics. What is new and Conclusion: The efficacy and safety of lamotrigine may be altered by concomitant administration of carbamazepine and valproic acid. The models developed may be useful for estimating doses of lamotrigine for individual patients to minimize clinically significant interactions. Therapeutic monitoring is advisable when those drugs are used concomitantly.
PB  - Wiley-Blackwell, Hoboken
T2  - Journal of Clinical Pharmacy and Therapeutics
T1  - Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics
VL  - 37
IS  - 6
SP  - 693
EP  - 697
DO  - 10.1111/j.1365-2710.2012.01351.x
ER  - 

@article{
author = "Brzaković, B. B. and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava and Martinović, Žarko J. and Pokrajac, Milena and Prostran, Milica",
year = "2012",
abstract = "What is known and Objective: Lamotrigine metabolism may be substantially altered with concomitant administration of valproic acid and/or carbamazepine. Such alterations may require the adjustment of lamotrigine dose to ensure optimal treatment efficacy and safety. Methods: The extent of lamotrigine interactions was investigated dependent on age, gender, weight and dose of concomitant carbamazepine and/or valproic acid in 65 patients with epilepsy. Lamotrigine plasma steady-state oral clearance (CLss/F) and area under the curve (AUCss) were calculated from the dose of drug, average steady-state concentration (Css) and interval of administration. Multiple regression analysis was used for the identification and quantification of factors that influenced lamotrigine pharmacokinetics. Results and Discussion: Age and dose of carbamazepine and valproic acid had significant influence on lamotrigine CLss/F and AUCss. Carbamazepine was associated with a dose-dependent increase and valproic acid with a dose-dependent decrease of lamotrigine metabolism rate. The effect of carbamazepine was more pronounced. Younger patients were expected to metabolize lamotrigine more rapidly whereas overweight patients may be less susceptible to interactions. Gender had no influence on lamotrigine pharmacokinetics. What is new and Conclusion: The efficacy and safety of lamotrigine may be altered by concomitant administration of carbamazepine and valproic acid. The models developed may be useful for estimating doses of lamotrigine for individual patients to minimize clinically significant interactions. Therapeutic monitoring is advisable when those drugs are used concomitantly.",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Journal of Clinical Pharmacy and Therapeutics",
title = "Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics",
volume = "37",
number = "6",
pages = "693-697",
doi = "10.1111/j.1365-2710.2012.01351.x"
}

Brzaković, B. B., Vezmar-Kovačević, S., Vučićević, K., Miljković, B., Martinović, Ž. J., Pokrajac, M.,& Prostran, M.. (2012). Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics. in Journal of Clinical Pharmacy and Therapeutics
Wiley-Blackwell, Hoboken., 37(6), 693-697.
https://doi.org/10.1111/j.1365-2710.2012.01351.x

Brzaković BB, Vezmar-Kovačević S, Vučićević K, Miljković B, Martinović ŽJ, Pokrajac M, Prostran M. Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics. in Journal of Clinical Pharmacy and Therapeutics. 2012;37(6):693-697.
doi:10.1111/j.1365-2710.2012.01351.x .

Brzaković, B. B., Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, Martinović, Žarko J., Pokrajac, Milena, Prostran, Milica, "Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics" in Journal of Clinical Pharmacy and Therapeutics, 37, no. 6 (2012):693-697,
https://doi.org/10.1111/j.1365-2710.2012.01351.x . .

TY  - JOUR
AU  - Rakić-Ignjatović, Anita
AU  - Miljković, Branislava
AU  - Todorović, Dejan
AU  - Timotijević, Ivana
AU  - Pokrajac, Milena
PY  - 2011
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1518
AB  - Because moclobemide pharmacokinetics vary considerably among individuals, monitoring of plasma concentrations lends insight into its pharmacokinetic behavior and enhances its rational use in clinical practice. The aim of this study was to evaluate whether single concentration-time points could adequately predict moclobemide systemic exposure. Pharmacokinetic data (full 7-point pharmacokinetic profiles), obtained from 21 depressive inpatients receiving moclobemide (150 mg 3 times daily), were randomly split into development (n = 18) and validation (n = 16) sets. Correlations between the single concentration-time points and the area under the concentration-time curve within a 6-hour dosing interval at steady-state (AUC(0-6)) were assessed by linear regression analyses. The predictive performance of single-point sampling strategies was evaluated in the validation set by mean prediction error, mean absolute error, and root mean square error. Plasma concentrations in the absorption phase yielded unsatisfactory predictions of moclobemide AUC(0-6). The best estimation of AUC(0-6) was achieved from concentrations at 4 and 6 hours following dosing. As the most reliable surrogate for moclobemide systemic exposure, concentrations at 4 and 6 hours should be used instead of predose trough concentrations as an indicator of between-patient variability and a guide for dose adjustments in specific clinical situations.
PB  - Wiley, Hoboken
T2  - Journal of Clinical Pharmacology
T1  - Evaluation of Single-Point Sampling Strategies for the Estimation of Moclobemide Exposure in Depressive Patients
VL  - 51
IS  - 5
SP  - 661
EP  - 671
DO  - 10.1177/0091270010372105
ER  - 

@article{
author = "Rakić-Ignjatović, Anita and Miljković, Branislava and Todorović, Dejan and Timotijević, Ivana and Pokrajac, Milena",
year = "2011",
abstract = "Because moclobemide pharmacokinetics vary considerably among individuals, monitoring of plasma concentrations lends insight into its pharmacokinetic behavior and enhances its rational use in clinical practice. The aim of this study was to evaluate whether single concentration-time points could adequately predict moclobemide systemic exposure. Pharmacokinetic data (full 7-point pharmacokinetic profiles), obtained from 21 depressive inpatients receiving moclobemide (150 mg 3 times daily), were randomly split into development (n = 18) and validation (n = 16) sets. Correlations between the single concentration-time points and the area under the concentration-time curve within a 6-hour dosing interval at steady-state (AUC(0-6)) were assessed by linear regression analyses. The predictive performance of single-point sampling strategies was evaluated in the validation set by mean prediction error, mean absolute error, and root mean square error. Plasma concentrations in the absorption phase yielded unsatisfactory predictions of moclobemide AUC(0-6). The best estimation of AUC(0-6) was achieved from concentrations at 4 and 6 hours following dosing. As the most reliable surrogate for moclobemide systemic exposure, concentrations at 4 and 6 hours should be used instead of predose trough concentrations as an indicator of between-patient variability and a guide for dose adjustments in specific clinical situations.",
publisher = "Wiley, Hoboken",
journal = "Journal of Clinical Pharmacology",
title = "Evaluation of Single-Point Sampling Strategies for the Estimation of Moclobemide Exposure in Depressive Patients",
volume = "51",
number = "5",
pages = "661-671",
doi = "10.1177/0091270010372105"
}

Rakić-Ignjatović, A., Miljković, B., Todorović, D., Timotijević, I.,& Pokrajac, M.. (2011). Evaluation of Single-Point Sampling Strategies for the Estimation of Moclobemide Exposure in Depressive Patients. in Journal of Clinical Pharmacology
Wiley, Hoboken., 51(5), 661-671.
https://doi.org/10.1177/0091270010372105

Rakić-Ignjatović A, Miljković B, Todorović D, Timotijević I, Pokrajac M. Evaluation of Single-Point Sampling Strategies for the Estimation of Moclobemide Exposure in Depressive Patients. in Journal of Clinical Pharmacology. 2011;51(5):661-671.
doi:10.1177/0091270010372105 .

Rakić-Ignjatović, Anita, Miljković, Branislava, Todorović, Dejan, Timotijević, Ivana, Pokrajac, Milena, "Evaluation of Single-Point Sampling Strategies for the Estimation of Moclobemide Exposure in Depressive Patients" in Journal of Clinical Pharmacology, 51, no. 5 (2011):661-671,
https://doi.org/10.1177/0091270010372105 . .

TY  - CONF
AU  - Rakić-Ignjatović, Anita
AU  - Miljković, Branislava
AU  - Todorović, Dejan
AU  - Timotijević, Ivana
AU  - Pokrajac, Milena
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1342
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - The effect of carbamazepine co-therapy on the extent of MAO-A inhibition by moclobemide in depressed patients
VL  - 20
IS  - Supplement 3
SP  - S373
EP  - S374
DO  - 10.1016/S0924-977X(10)70526-5
ER  - 

@conference{
author = "Rakić-Ignjatović, Anita and Miljković, Branislava and Todorović, Dejan and Timotijević, Ivana and Pokrajac, Milena",
year = "2010",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "The effect of carbamazepine co-therapy on the extent of MAO-A inhibition by moclobemide in depressed patients",
volume = "20",
number = "Supplement 3",
pages = "S373-S374",
doi = "10.1016/S0924-977X(10)70526-5"
}

Rakić-Ignjatović, A., Miljković, B., Todorović, D., Timotijević, I.,& Pokrajac, M.. (2010). The effect of carbamazepine co-therapy on the extent of MAO-A inhibition by moclobemide in depressed patients. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 20(Supplement 3), S373-S374.
https://doi.org/10.1016/S0924-977X(10)70526-5

Rakić-Ignjatović A, Miljković B, Todorović D, Timotijević I, Pokrajac M. The effect of carbamazepine co-therapy on the extent of MAO-A inhibition by moclobemide in depressed patients. in European Neuropsychopharmacology. 2010;20(Supplement 3):S373-S374.
doi:10.1016/S0924-977X(10)70526-5 .

Rakić-Ignjatović, Anita, Miljković, Branislava, Todorović, Dejan, Timotijević, Ivana, Pokrajac, Milena, "The effect of carbamazepine co-therapy on the extent of MAO-A inhibition by moclobemide in depressed patients" in European Neuropsychopharmacology, 20, no. Supplement 3 (2010):S373-S374,
https://doi.org/10.1016/S0924-977X(10)70526-5 . .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Prostran, Milica
AU  - Martinović, Žarko J.
AU  - Veličković, Ružica
AU  - Grabnar, Iztok
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1348
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach
VL  - 20
IS  - Supplement 3
SP  - S247
EP  - S248
DO  - 10.1016/S0924-977X(10)70310-2
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Pokrajac, Milena and Prostran, Milica and Martinović, Žarko J. and Veličković, Ružica and Grabnar, Iztok",
year = "2010",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach",
volume = "20",
number = "Supplement 3",
pages = "S247-S248",
doi = "10.1016/S0924-977X(10)70310-2"
}

Vučićević, K., Miljković, B., Pokrajac, M., Prostran, M., Martinović, Ž. J., Veličković, R.,& Grabnar, I.. (2010). Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 20(Supplement 3), S247-S248.
https://doi.org/10.1016/S0924-977X(10)70310-2

Vučićević K, Miljković B, Pokrajac M, Prostran M, Martinović ŽJ, Veličković R, Grabnar I. Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach. in European Neuropsychopharmacology. 2010;20(Supplement 3):S247-S248.
doi:10.1016/S0924-977X(10)70310-2 .

Vučićević, Katarina, Miljković, Branislava, Pokrajac, Milena, Prostran, Milica, Martinović, Žarko J., Veličković, Ružica, Grabnar, Iztok, "Assessment of benzodiazepines-valproic acid pharmacokinetic interaction in adult epileptic patients: population approach" in European Neuropsychopharmacology, 20, no. Supplement 3 (2010):S247-S248,
https://doi.org/10.1016/S0924-977X(10)70310-2 . .

TY  - JOUR
AU  - Rakić-Ignjatović, Anita
AU  - Miljković, Branislava
AU  - Ilić, Marija
AU  - Pokrajac, Milena
AU  - Prostran, Milica
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1448
AB  - In recent years there has been a significant paradigm shift in pre-clinical drug metabolism studies. Most importantly, this has included a reduced reliance on animal models and increased use of human tissues (i.e. human liver microsomes and other subcellular fractions, primary culture of human hepatocytes, recombinant human enzymes/transgenic cell lines). During the pre-clinical phase of drug development such studies assess the metabolic stability, reaction phenotyping (elucidation of specific enzyme(s) involved in phase I and II metabolism), metabolic fingerprinting (identification and structural determination of the metabolic end products) and drug interaction issues pertaining to enzyme inhibition and induction. Such studies are now increasingly being used for qualitative and quantitative prediction of drug biotransformation in humans and in the identification of likely determinants of metabolism following drug administration to humans, including possible drug interactions. Results from a multitude of such experiments help in identifying/optimizing a lead compound and rejecting compounds that are likely to be problematic with regards to causing toxicity or adverse drug-drug interactions. Therefore, well designed in vitro methodologies are vital to reducing the number of human trials during the late stages of drug development.
AB  - Upotreba eksperimentalnih životinja i in vitro modela životinjskog porekla u pretkliničkim studijama metabolizma lekova je u velikoj meri potisnuta in vitro eksperimentalnim modelima poreklom od humanih tkiva. Danas se najviše koriste komercijalno dostupni preparati ljudske jetre, kao što su rekombinantni enzimi/transgenske ćelijske linije, subcelularne frakcije (mikrozomi, citozol i S9 frakcija) i primarni hepatociti. Primenom ovih modela u toku pretkliničke faze razvoja novog leka ispituje se stepen metaboličke transformacije leka, vrši se fenotipizacija metaboličkih reakcija (identifikacija specifičnog/ih enzima uključenih u I i II fazu metabolizma leka), određivanje metaboličkog profila (metabolic fingerprinting - identifikacija i određivanje strukture krajnjih produkata metabolizma leka) i razmatra se potencijal za stupanje u interakcije sa drugim lekovima, sa aspekta inhibicije i indukcije metaboličkih enzima. Primena in vitro - in vivo korelacije uz dobro razumevanje farmakokinetičkih principa omogućava predviđanje metabolizma i interakcija lekova in vivo na osnovu dobijenih in vitro podataka. Rezultati brojnih in vitro eksperimenata imaju značajnu ulogu u identifikaciji/optimizaciji vodećeg kandidata za novi lek. Dobro dizajnirane in vitro studije omogućavaju smanjenje broja kliničkih ispitivanja kod ljudi, koja se sprovode u kasnijim fazama razvoja leka.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Role of metabolism in drug development: In vitro studies
T1  - Značaj izučavanja metabolizma u razvoju novih lekova - in vitro pristup
VL  - 60
IS  - 4
SP  - 353
EP  - 372
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1448
ER  - 

@article{
author = "Rakić-Ignjatović, Anita and Miljković, Branislava and Ilić, Marija and Pokrajac, Milena and Prostran, Milica",
year = "2010",
abstract = "In recent years there has been a significant paradigm shift in pre-clinical drug metabolism studies. Most importantly, this has included a reduced reliance on animal models and increased use of human tissues (i.e. human liver microsomes and other subcellular fractions, primary culture of human hepatocytes, recombinant human enzymes/transgenic cell lines). During the pre-clinical phase of drug development such studies assess the metabolic stability, reaction phenotyping (elucidation of specific enzyme(s) involved in phase I and II metabolism), metabolic fingerprinting (identification and structural determination of the metabolic end products) and drug interaction issues pertaining to enzyme inhibition and induction. Such studies are now increasingly being used for qualitative and quantitative prediction of drug biotransformation in humans and in the identification of likely determinants of metabolism following drug administration to humans, including possible drug interactions. Results from a multitude of such experiments help in identifying/optimizing a lead compound and rejecting compounds that are likely to be problematic with regards to causing toxicity or adverse drug-drug interactions. Therefore, well designed in vitro methodologies are vital to reducing the number of human trials during the late stages of drug development., Upotreba eksperimentalnih životinja i in vitro modela životinjskog porekla u pretkliničkim studijama metabolizma lekova je u velikoj meri potisnuta in vitro eksperimentalnim modelima poreklom od humanih tkiva. Danas se najviše koriste komercijalno dostupni preparati ljudske jetre, kao što su rekombinantni enzimi/transgenske ćelijske linije, subcelularne frakcije (mikrozomi, citozol i S9 frakcija) i primarni hepatociti. Primenom ovih modela u toku pretkliničke faze razvoja novog leka ispituje se stepen metaboličke transformacije leka, vrši se fenotipizacija metaboličkih reakcija (identifikacija specifičnog/ih enzima uključenih u I i II fazu metabolizma leka), određivanje metaboličkog profila (metabolic fingerprinting - identifikacija i određivanje strukture krajnjih produkata metabolizma leka) i razmatra se potencijal za stupanje u interakcije sa drugim lekovima, sa aspekta inhibicije i indukcije metaboličkih enzima. Primena in vitro - in vivo korelacije uz dobro razumevanje farmakokinetičkih principa omogućava predviđanje metabolizma i interakcija lekova in vivo na osnovu dobijenih in vitro podataka. Rezultati brojnih in vitro eksperimenata imaju značajnu ulogu u identifikaciji/optimizaciji vodećeg kandidata za novi lek. Dobro dizajnirane in vitro studije omogućavaju smanjenje broja kliničkih ispitivanja kod ljudi, koja se sprovode u kasnijim fazama razvoja leka.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Role of metabolism in drug development: In vitro studies, Značaj izučavanja metabolizma u razvoju novih lekova - in vitro pristup",
volume = "60",
number = "4",
pages = "353-372",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1448"
}

Rakić-Ignjatović, A., Miljković, B., Ilić, M., Pokrajac, M.,& Prostran, M.. (2010). Role of metabolism in drug development: In vitro studies. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 60(4), 353-372.
https://hdl.handle.net/21.15107/rcub_farfar_1448

Rakić-Ignjatović A, Miljković B, Ilić M, Pokrajac M, Prostran M. Role of metabolism in drug development: In vitro studies. in Arhiv za farmaciju. 2010;60(4):353-372.
https://hdl.handle.net/21.15107/rcub_farfar_1448 .

Rakić-Ignjatović, Anita, Miljković, Branislava, Ilić, Marija, Pokrajac, Milena, Prostran, Milica, "Role of metabolism in drug development: In vitro studies" in Arhiv za farmaciju, 60, no. 4 (2010):353-372,
https://hdl.handle.net/21.15107/rcub_farfar_1448 .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Grabnar, Iztok
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1171
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Effect of topiramate on valproic acid clearance in adult patients with epilepsy: a population pharmacokinetic study
VL  - 19
IS  - Supplement 3
SP  - S271
EP  - S271
DO  - 10.1016/S0924-977X(09)70394-3
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Pokrajac, Milena and Grabnar, Iztok",
year = "2009",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Effect of topiramate on valproic acid clearance in adult patients with epilepsy: a population pharmacokinetic study",
volume = "19",
number = "Supplement 3",
pages = "S271-S271",
doi = "10.1016/S0924-977X(09)70394-3"
}

Vučićević, K., Miljković, B., Pokrajac, M.,& Grabnar, I.. (2009). Effect of topiramate on valproic acid clearance in adult patients with epilepsy: a population pharmacokinetic study. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 19(Supplement 3), S271-S271.
https://doi.org/10.1016/S0924-977X(09)70394-3

Vučićević K, Miljković B, Pokrajac M, Grabnar I. Effect of topiramate on valproic acid clearance in adult patients with epilepsy: a population pharmacokinetic study. in European Neuropsychopharmacology. 2009;19(Supplement 3):S271-S271.
doi:10.1016/S0924-977X(09)70394-3 .

Vučićević, Katarina, Miljković, Branislava, Pokrajac, Milena, Grabnar, Iztok, "Effect of topiramate on valproic acid clearance in adult patients with epilepsy: a population pharmacokinetic study" in European Neuropsychopharmacology, 19, no. Supplement 3 (2009):S271-S271,
https://doi.org/10.1016/S0924-977X(09)70394-3 . .

TY  - CONF
AU  - Rakić-Ignjatović, Anita
AU  - Miljković, Branislava
AU  - Todorović, Dejan
AU  - Timotijević, Ivana
AU  - Pokrajac, Milena
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1174
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Moclobemide dosage regimen adjustment in depressive patients on carbamazepine co-therapy
VL  - 19
IS  - Supplement 3
SP  - S414
EP  - S414
DO  - 10.1016/S0924-977X(09)70640-6
ER  - 

@conference{
author = "Rakić-Ignjatović, Anita and Miljković, Branislava and Todorović, Dejan and Timotijević, Ivana and Pokrajac, Milena",
year = "2009",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Moclobemide dosage regimen adjustment in depressive patients on carbamazepine co-therapy",
volume = "19",
number = "Supplement 3",
pages = "S414-S414",
doi = "10.1016/S0924-977X(09)70640-6"
}

Rakić-Ignjatović, A., Miljković, B., Todorović, D., Timotijević, I.,& Pokrajac, M.. (2009). Moclobemide dosage regimen adjustment in depressive patients on carbamazepine co-therapy. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 19(Supplement 3), S414-S414.
https://doi.org/10.1016/S0924-977X(09)70640-6

Rakić-Ignjatović A, Miljković B, Todorović D, Timotijević I, Pokrajac M. Moclobemide dosage regimen adjustment in depressive patients on carbamazepine co-therapy. in European Neuropsychopharmacology. 2009;19(Supplement 3):S414-S414.
doi:10.1016/S0924-977X(09)70640-6 .

Rakić-Ignjatović, Anita, Miljković, Branislava, Todorović, Dejan, Timotijević, Ivana, Pokrajac, Milena, "Moclobemide dosage regimen adjustment in depressive patients on carbamazepine co-therapy" in European Neuropsychopharmacology, 19, no. Supplement 3 (2009):S414-S414,
https://doi.org/10.1016/S0924-977X(09)70640-6 . .

TY  - JOUR
AU  - Vezmar, Sandra
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Timotijević, Ivana
AU  - Prostran, Milica
AU  - Todorović, Zoran
AU  - Pokrajac, Milena
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1232
AB  - Although often necessary for obtaining remission following major depressive disorder, combined antidepressant treatment Is frequently associated with drug interactions and enhanced adverse drug effects. We investigated pharmacokinetic interactions following combined fluvoxamine and amitriptyline treatment and their impact on therapeutic efficacy and tolerability. Twenty-two inpatients with major depression [Hamilton Depression Scale (HAM-D) rating >= 18] were treated with either amitriptyline (75 mg/day), fluvoxamine (100 mg/day) or both. Blood samples, for determination of amitriptyline, its major metabolite nortritpyline, and fluvoxamine, were obtained after single dose administration and in steady-state. Therapeutic efficacy was evaluated using HAM-D and adverse drug effects were evaluated using the clinical global impression scale. Following combined treatment, steady-state plasma levels of nortriptyline were significantly decreased compared to monotherapy. HAM-D scores after two-week treatment showed that there was a better response to combined treatment. There was no significant difference in severity of adverse effects among groups. We observed a pharmcokinetic interaction between fluvoxamine and amitritpyline resulting in impaired metabolism of the later. However, no signifcant impact of the interaction on treatment safety was observed. Moreover, concomitant use of amitriptyline at 75mg/day and fluvoxamine at 100 mg/day was well tolerated with a more prompt and stronger onset of clinical response compared to monotherapy in patients with major depression.
PB  - Japanese Pharmacological Soc, Kyoto
T2  - Journal of Pharmacological Sciences
T1  - Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression
VL  - 110
IS  - 1
SP  - 98
EP  - 104
DO  - 10.1254/jphs.09013FP
ER  - 

@article{
author = "Vezmar, Sandra and Miljković, Branislava and Vučićević, Katarina and Timotijević, Ivana and Prostran, Milica and Todorović, Zoran and Pokrajac, Milena",
year = "2009",
abstract = "Although often necessary for obtaining remission following major depressive disorder, combined antidepressant treatment Is frequently associated with drug interactions and enhanced adverse drug effects. We investigated pharmacokinetic interactions following combined fluvoxamine and amitriptyline treatment and their impact on therapeutic efficacy and tolerability. Twenty-two inpatients with major depression [Hamilton Depression Scale (HAM-D) rating >= 18] were treated with either amitriptyline (75 mg/day), fluvoxamine (100 mg/day) or both. Blood samples, for determination of amitriptyline, its major metabolite nortritpyline, and fluvoxamine, were obtained after single dose administration and in steady-state. Therapeutic efficacy was evaluated using HAM-D and adverse drug effects were evaluated using the clinical global impression scale. Following combined treatment, steady-state plasma levels of nortriptyline were significantly decreased compared to monotherapy. HAM-D scores after two-week treatment showed that there was a better response to combined treatment. There was no significant difference in severity of adverse effects among groups. We observed a pharmcokinetic interaction between fluvoxamine and amitritpyline resulting in impaired metabolism of the later. However, no signifcant impact of the interaction on treatment safety was observed. Moreover, concomitant use of amitriptyline at 75mg/day and fluvoxamine at 100 mg/day was well tolerated with a more prompt and stronger onset of clinical response compared to monotherapy in patients with major depression.",
publisher = "Japanese Pharmacological Soc, Kyoto",
journal = "Journal of Pharmacological Sciences",
title = "Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression",
volume = "110",
number = "1",
pages = "98-104",
doi = "10.1254/jphs.09013FP"
}

Vezmar, S., Miljković, B., Vučićević, K., Timotijević, I., Prostran, M., Todorović, Z.,& Pokrajac, M.. (2009). Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression. in Journal of Pharmacological Sciences
Japanese Pharmacological Soc, Kyoto., 110(1), 98-104.
https://doi.org/10.1254/jphs.09013FP

Vezmar S, Miljković B, Vučićević K, Timotijević I, Prostran M, Todorović Z, Pokrajac M. Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression. in Journal of Pharmacological Sciences. 2009;110(1):98-104.
doi:10.1254/jphs.09013FP .

Vezmar, Sandra, Miljković, Branislava, Vučićević, Katarina, Timotijević, Ivana, Prostran, Milica, Todorović, Zoran, Pokrajac, Milena, "Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression" in Journal of Pharmacological Sciences, 110, no. 1 (2009):98-104,
https://doi.org/10.1254/jphs.09013FP . .

TY  - JOUR
AU  - Rakić-Ignjatović, Anita
AU  - Miljković, Branislava
AU  - Todorović, Dejan
AU  - Timotijević, Ivana
AU  - Pokrajac, Milena
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1249
AB  - WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT center dot Moclobemide (MCB) undergoes extensive both presystemic and systemic metabolism that can be affected by concomitant drugs. center dot Valproic acid (VPA) and carbamazepine (CBZ) have been found to interact with psychotropic medications of all classes and many other drugs; VPA acts as a broad-spectrum inhibitor, and CBZ as a potent inducer of a variety of drug-metabolizing enzymes. center dot There have been no previous studies designed to investigate a potential pharmacokinetic (PK) interaction between MCB and VPA or CBZ; however, these agents are likely to be used concomitantly for the treatment of depressive disorders. WHAT THIS STUDY ADDS center dot VPA does not significantly affect PK or metabolism of MCB at steady state. center dot CBZ significantly decreases MCB exposure. This effect is time-dependent, being more pronounced after 3-5 weeks of co-administration. To assess the impact of valproic acid (VPA) and carbamazepine (CBZ) on moclobemide (MCB) pharmacokinetics (PK) and metabolism at steady state in depressive patients. Twenty-one inpatients with recurrent endogenous depression received MCB (150 mg t.i.d.), either as monotherapy or in combination with VPA (500 mg b.i.d.) or CBZ (200 mg b.i.d.) in a nonrandomized manner. Steady-state plasma PK parameters of MCB and its two metabolites, Ro 12-8095 and Ro 12-5637, were derived. Clinical assessments of treatment efficacy were performed weekly using standard depression rating scales. CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C-max by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P  lt  0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P  lt  0.05) after 4 weeks of co-administration. MCB through concentrations were also decreased, on average by 41% (from 0.950 to 0.559 mg l(-1); 95% CI -0.77479, -0.03301; P  lt  0.05). However, the efficacy in this group of patients was not inferior to the controls, for several possible reasons. Overall tolerability of all study medications was good. VPA does not significantly affect PK or metabolism of MCB, whereas CBZ time-dependently decreases MCB exposure, probably by inducing metabolism of MCB and its major plasma metabolite. The actual clinical relevance of the observed MCB-CBZ PK interaction needs to be further evaluated in a more comprehensive study.
PB  - Wiley, Hoboken
T2  - British Journal of Clinical Pharmacology
T1  - Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study
VL  - 67
IS  - 2
SP  - 199
EP  - 208
DO  - 10.1111/j.1365-2125.2008.03326.x
ER  - 

@article{
author = "Rakić-Ignjatović, Anita and Miljković, Branislava and Todorović, Dejan and Timotijević, Ivana and Pokrajac, Milena",
year = "2009",
abstract = "WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT center dot Moclobemide (MCB) undergoes extensive both presystemic and systemic metabolism that can be affected by concomitant drugs. center dot Valproic acid (VPA) and carbamazepine (CBZ) have been found to interact with psychotropic medications of all classes and many other drugs; VPA acts as a broad-spectrum inhibitor, and CBZ as a potent inducer of a variety of drug-metabolizing enzymes. center dot There have been no previous studies designed to investigate a potential pharmacokinetic (PK) interaction between MCB and VPA or CBZ; however, these agents are likely to be used concomitantly for the treatment of depressive disorders. WHAT THIS STUDY ADDS center dot VPA does not significantly affect PK or metabolism of MCB at steady state. center dot CBZ significantly decreases MCB exposure. This effect is time-dependent, being more pronounced after 3-5 weeks of co-administration. To assess the impact of valproic acid (VPA) and carbamazepine (CBZ) on moclobemide (MCB) pharmacokinetics (PK) and metabolism at steady state in depressive patients. Twenty-one inpatients with recurrent endogenous depression received MCB (150 mg t.i.d.), either as monotherapy or in combination with VPA (500 mg b.i.d.) or CBZ (200 mg b.i.d.) in a nonrandomized manner. Steady-state plasma PK parameters of MCB and its two metabolites, Ro 12-8095 and Ro 12-5637, were derived. Clinical assessments of treatment efficacy were performed weekly using standard depression rating scales. CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C-max by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P  lt  0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P  lt  0.05) after 4 weeks of co-administration. MCB through concentrations were also decreased, on average by 41% (from 0.950 to 0.559 mg l(-1); 95% CI -0.77479, -0.03301; P  lt  0.05). However, the efficacy in this group of patients was not inferior to the controls, for several possible reasons. Overall tolerability of all study medications was good. VPA does not significantly affect PK or metabolism of MCB, whereas CBZ time-dependently decreases MCB exposure, probably by inducing metabolism of MCB and its major plasma metabolite. The actual clinical relevance of the observed MCB-CBZ PK interaction needs to be further evaluated in a more comprehensive study.",
publisher = "Wiley, Hoboken",
journal = "British Journal of Clinical Pharmacology",
title = "Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study",
volume = "67",
number = "2",
pages = "199-208",
doi = "10.1111/j.1365-2125.2008.03326.x"
}

Rakić-Ignjatović, A., Miljković, B., Todorović, D., Timotijević, I.,& Pokrajac, M.. (2009). Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. in British Journal of Clinical Pharmacology
Wiley, Hoboken., 67(2), 199-208.
https://doi.org/10.1111/j.1365-2125.2008.03326.x

Rakić-Ignjatović A, Miljković B, Todorović D, Timotijević I, Pokrajac M. Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. in British Journal of Clinical Pharmacology. 2009;67(2):199-208.
doi:10.1111/j.1365-2125.2008.03326.x .

Rakić-Ignjatović, Anita, Miljković, Branislava, Todorović, Dejan, Timotijević, Ivana, Pokrajac, Milena, "Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study" in British Journal of Clinical Pharmacology, 67, no. 2 (2009):199-208,
https://doi.org/10.1111/j.1365-2125.2008.03326.x . .

TY  - JOUR
AU  - Rakić-Ignjatović, Anita
AU  - Nikolić, Katarina
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Agbaba, Danica
AU  - Prostran, Milica
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1260
AB  - A SPE-HPLC-UV method for determination of moclobemide and its major metabolites, Ro 12-5637 and Ro 12-8095, in human plasma had been developed previously and its selectivity was evaluated against the most frequently coadministered drugs. The objective of the present work was to develop a quantitative structure retention relationship (QSRR) model capable of providing good predictions of chromatographic behaviour of other related potentially interfering drugs, based on the previously generated data, in order to further improve the clinical applicability of the existing method. Moreover, the most critical factors affecting SPE and chromatographic separations of moclobemide and its metabolites were evaluated and discussed, taking into account molecular properties of the analyzed compounds.
PB  - Taylor & Francis Inc, Philadelphia
T2  - Journal of Liquid Chromatography & Related Technologies
T1  - Determination of Moclobemide and its Metabolites in Human Plasma by SPE-HPLC-UV: Evaluation of Critical Experimental Conditions and QSRR Study
VL  - 32
IS  - 14
SP  - 2080
EP  - 2096
DO  - 10.1080/10826070903126963
ER  - 

@article{
author = "Rakić-Ignjatović, Anita and Nikolić, Katarina and Miljković, Branislava and Pokrajac, Milena and Agbaba, Danica and Prostran, Milica",
year = "2009",
abstract = "A SPE-HPLC-UV method for determination of moclobemide and its major metabolites, Ro 12-5637 and Ro 12-8095, in human plasma had been developed previously and its selectivity was evaluated against the most frequently coadministered drugs. The objective of the present work was to develop a quantitative structure retention relationship (QSRR) model capable of providing good predictions of chromatographic behaviour of other related potentially interfering drugs, based on the previously generated data, in order to further improve the clinical applicability of the existing method. Moreover, the most critical factors affecting SPE and chromatographic separations of moclobemide and its metabolites were evaluated and discussed, taking into account molecular properties of the analyzed compounds.",
publisher = "Taylor & Francis Inc, Philadelphia",
journal = "Journal of Liquid Chromatography & Related Technologies",
title = "Determination of Moclobemide and its Metabolites in Human Plasma by SPE-HPLC-UV: Evaluation of Critical Experimental Conditions and QSRR Study",
volume = "32",
number = "14",
pages = "2080-2096",
doi = "10.1080/10826070903126963"
}

Rakić-Ignjatović, A., Nikolić, K., Miljković, B., Pokrajac, M., Agbaba, D.,& Prostran, M.. (2009). Determination of Moclobemide and its Metabolites in Human Plasma by SPE-HPLC-UV: Evaluation of Critical Experimental Conditions and QSRR Study. in Journal of Liquid Chromatography & Related Technologies
Taylor & Francis Inc, Philadelphia., 32(14), 2080-2096.
https://doi.org/10.1080/10826070903126963

Rakić-Ignjatović A, Nikolić K, Miljković B, Pokrajac M, Agbaba D, Prostran M. Determination of Moclobemide and its Metabolites in Human Plasma by SPE-HPLC-UV: Evaluation of Critical Experimental Conditions and QSRR Study. in Journal of Liquid Chromatography & Related Technologies. 2009;32(14):2080-2096.
doi:10.1080/10826070903126963 .

Rakić-Ignjatović, Anita, Nikolić, Katarina, Miljković, Branislava, Pokrajac, Milena, Agbaba, Danica, Prostran, Milica, "Determination of Moclobemide and its Metabolites in Human Plasma by SPE-HPLC-UV: Evaluation of Critical Experimental Conditions and QSRR Study" in Journal of Liquid Chromatography & Related Technologies, 32, no. 14 (2009):2080-2096,
https://doi.org/10.1080/10826070903126963 . .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Petronijević, Marija
AU  - Pokrajac, Milena
AU  - Veličković, Ružica
AU  - Mrhar, Ales
AU  - Grabnar, Iztok
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1240
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - No effect of gender on carbamazepine elimination-population approach
VL  - 31
IS  - 1
SP  - 118
EP  - 119
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1240
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Petronijević, Marija and Pokrajac, Milena and Veličković, Ružica and Mrhar, Ales and Grabnar, Iztok",
year = "2009",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "No effect of gender on carbamazepine elimination-population approach",
volume = "31",
number = "1",
pages = "118-119",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1240"
}

Vučićević, K., Miljković, B., Petronijević, M., Pokrajac, M., Veličković, R., Mrhar, A.,& Grabnar, I.. (2009). No effect of gender on carbamazepine elimination-population approach. in Pharmacy World & Science
Springer, Dordrecht., 31(1), 118-119.
https://hdl.handle.net/21.15107/rcub_farfar_1240

Vučićević K, Miljković B, Petronijević M, Pokrajac M, Veličković R, Mrhar A, Grabnar I. No effect of gender on carbamazepine elimination-population approach. in Pharmacy World & Science. 2009;31(1):118-119.
https://hdl.handle.net/21.15107/rcub_farfar_1240 .

Vučićević, Katarina, Miljković, Branislava, Petronijević, Marija, Pokrajac, Milena, Veličković, Ružica, Mrhar, Ales, Grabnar, Iztok, "No effect of gender on carbamazepine elimination-population approach" in Pharmacy World & Science, 31, no. 1 (2009):118-119,
https://hdl.handle.net/21.15107/rcub_farfar_1240 .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Grabnar, Iztok
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1219
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - Effect of patient weight and carbamazepine daily dose on carbamazepine clearance-a population pharmacokinetic study
VL  - 31
IS  - 2
SP  - 332
EP  - 333
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1219
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Pokrajac, Milena and Grabnar, Iztok",
year = "2009",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "Effect of patient weight and carbamazepine daily dose on carbamazepine clearance-a population pharmacokinetic study",
volume = "31",
number = "2",
pages = "332-333",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1219"
}

Vučićević, K., Miljković, B., Pokrajac, M.,& Grabnar, I.. (2009). Effect of patient weight and carbamazepine daily dose on carbamazepine clearance-a population pharmacokinetic study. in Pharmacy World & Science
Springer, Dordrecht., 31(2), 332-333.
https://hdl.handle.net/21.15107/rcub_farfar_1219

Vučićević K, Miljković B, Pokrajac M, Grabnar I. Effect of patient weight and carbamazepine daily dose on carbamazepine clearance-a population pharmacokinetic study. in Pharmacy World & Science. 2009;31(2):332-333.
https://hdl.handle.net/21.15107/rcub_farfar_1219 .

Vučićević, Katarina, Miljković, Branislava, Pokrajac, Milena, Grabnar, Iztok, "Effect of patient weight and carbamazepine daily dose on carbamazepine clearance-a population pharmacokinetic study" in Pharmacy World & Science, 31, no. 2 (2009):332-333,
https://hdl.handle.net/21.15107/rcub_farfar_1219 .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Prostran, Milica
AU  - Martinović, Žarko J.
AU  - Grabnar, Iztok
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1211
AB  - Monitoring valproic acid (VPA) concentrations is especially challenging due to its highly variable pharmacokinetics (PK) and complex interactions with other antiepileptic drugs. We used sparse routine therapeutic drug monitoring data (n = 200) from 129 adults with epilepsy to develop a population PK model of VPA, and determine the factors that influence its clearance (CL/F). Patients were on mono VPA therapy, or were concomitantly treated with carbamazepine, phenobarbital, topiramate (TPR), lamotrigine or benzodiazepines. A one-compartment model with first-order absorption and elimination was used to fit the concentration-time VPA data. Estimates generated by NONMEM indicated that VPA CL/F was influenced by the patients' body weight (increases with the 0.556 exponent), VPA daily dose (if it is greater than 1000 mg/day, CL/F increases by 43%), and co-therapy with TPR (lowering CL/F for 23%). The interindividual variability in VPA CL/F was modeled with exponentional error model. The estimated coefficient of variation was 31.9%, while the residual variability was 23.8% for the proportional and 13.2 mg/l for the additive component. The model was validated in a separate set of 24 patients, and the predictive performance was evaluated, that indicated unbias and acceptable precision. This study confirms the interaction of VPA with TPR, which is presumably dependent on VPA dose.
PB  - Elsevier Science BV, Amsterdam
T2  - European Journal of Pharmaceutical Sciences
T1  - The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling
VL  - 38
IS  - 5
SP  - 512
EP  - 518
DO  - 10.1016/j.ejps.2009.09.017
ER  - 

@article{
author = "Vučićević, Katarina and Miljković, Branislava and Pokrajac, Milena and Prostran, Milica and Martinović, Žarko J. and Grabnar, Iztok",
year = "2009",
abstract = "Monitoring valproic acid (VPA) concentrations is especially challenging due to its highly variable pharmacokinetics (PK) and complex interactions with other antiepileptic drugs. We used sparse routine therapeutic drug monitoring data (n = 200) from 129 adults with epilepsy to develop a population PK model of VPA, and determine the factors that influence its clearance (CL/F). Patients were on mono VPA therapy, or were concomitantly treated with carbamazepine, phenobarbital, topiramate (TPR), lamotrigine or benzodiazepines. A one-compartment model with first-order absorption and elimination was used to fit the concentration-time VPA data. Estimates generated by NONMEM indicated that VPA CL/F was influenced by the patients' body weight (increases with the 0.556 exponent), VPA daily dose (if it is greater than 1000 mg/day, CL/F increases by 43%), and co-therapy with TPR (lowering CL/F for 23%). The interindividual variability in VPA CL/F was modeled with exponentional error model. The estimated coefficient of variation was 31.9%, while the residual variability was 23.8% for the proportional and 13.2 mg/l for the additive component. The model was validated in a separate set of 24 patients, and the predictive performance was evaluated, that indicated unbias and acceptable precision. This study confirms the interaction of VPA with TPR, which is presumably dependent on VPA dose.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmaceutical Sciences",
title = "The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling",
volume = "38",
number = "5",
pages = "512-518",
doi = "10.1016/j.ejps.2009.09.017"
}

Vučićević, K., Miljković, B., Pokrajac, M., Prostran, M., Martinović, Ž. J.,& Grabnar, I.. (2009). The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling. in European Journal of Pharmaceutical Sciences
Elsevier Science BV, Amsterdam., 38(5), 512-518.
https://doi.org/10.1016/j.ejps.2009.09.017

Vučićević K, Miljković B, Pokrajac M, Prostran M, Martinović ŽJ, Grabnar I. The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling. in European Journal of Pharmaceutical Sciences. 2009;38(5):512-518.
doi:10.1016/j.ejps.2009.09.017 .

Vučićević, Katarina, Miljković, Branislava, Pokrajac, Milena, Prostran, Milica, Martinović, Žarko J., Grabnar, Iztok, "The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling" in European Journal of Pharmaceutical Sciences, 38, no. 5 (2009):512-518,
https://doi.org/10.1016/j.ejps.2009.09.017 . .

TY  - CONF
AU  - Rakić-Ignjatović, Anita
AU  - Miljković, Branislava
AU  - Todorović, Dejan
AU  - Timotijević, Ivana
AU  - Pokrajac, Milena
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1030
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Are moclobemide trough concentrations an adequate predictor of the systemic drug exposure
VL  - 18
IS  - Supplement 4
SP  - S337
EP  - S338
DO  - 10.1016/S0924-977X(08)70469-3
ER  - 

@conference{
author = "Rakić-Ignjatović, Anita and Miljković, Branislava and Todorović, Dejan and Timotijević, Ivana and Pokrajac, Milena",
year = "2008",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Are moclobemide trough concentrations an adequate predictor of the systemic drug exposure",
volume = "18",
number = "Supplement 4",
pages = "S337-S338",
doi = "10.1016/S0924-977X(08)70469-3"
}

Rakić-Ignjatović, A., Miljković, B., Todorović, D., Timotijević, I.,& Pokrajac, M.. (2008). Are moclobemide trough concentrations an adequate predictor of the systemic drug exposure. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 18(Supplement 4), S337-S338.
https://doi.org/10.1016/S0924-977X(08)70469-3

Rakić-Ignjatović A, Miljković B, Todorović D, Timotijević I, Pokrajac M. Are moclobemide trough concentrations an adequate predictor of the systemic drug exposure. in European Neuropsychopharmacology. 2008;18(Supplement 4):S337-S338.
doi:10.1016/S0924-977X(08)70469-3 .

Rakić-Ignjatović, Anita, Miljković, Branislava, Todorović, Dejan, Timotijević, Ivana, Pokrajac, Milena, "Are moclobemide trough concentrations an adequate predictor of the systemic drug exposure" in European Neuropsychopharmacology, 18, no. Supplement 4 (2008):S337-S338,
https://doi.org/10.1016/S0924-977X(08)70469-3 . .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Petronijević, Marija
AU  - Pokrajac, Milena
AU  - Mrhar, Ales
AU  - Grabnar, Iztok
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1109
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study
VL  - 30
IS  - 5
SP  - 673
EP  - 674
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1109
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Petronijević, Marija and Pokrajac, Milena and Mrhar, Ales and Grabnar, Iztok",
year = "2008",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study",
volume = "30",
number = "5",
pages = "673-674",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1109"
}

Vučićević, K., Miljković, B., Petronijević, M., Pokrajac, M., Mrhar, A.,& Grabnar, I.. (2008). Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study. in Pharmacy World & Science
Springer, Dordrecht., 30(5), 673-674.
https://hdl.handle.net/21.15107/rcub_farfar_1109

Vučićević K, Miljković B, Petronijević M, Pokrajac M, Mrhar A, Grabnar I. Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study. in Pharmacy World & Science. 2008;30(5):673-674.
https://hdl.handle.net/21.15107/rcub_farfar_1109 .

Vučićević, Katarina, Miljković, Branislava, Petronijević, Marija, Pokrajac, Milena, Mrhar, Ales, Grabnar, Iztok, "Effect of co-treatment with valproic acid on carbamazepine elimination in epileptic patients a population pharmacokinetic study" in Pharmacy World & Science, 30, no. 5 (2008):673-674,
https://hdl.handle.net/21.15107/rcub_farfar_1109 .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Petronijević, M.
AU  - Pokrajac, Milena
AU  - Veličković, Ružica
AU  - Grabnar, Iztok
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/896
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study
VL  - 17
IS  - Supplement 4
SP  - S261
EP  - S262
DO  - 10.1016/S0924-977X(07)70358-9
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Petronijević, M. and Pokrajac, Milena and Veličković, Ružica and Grabnar, Iztok",
year = "2007",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study",
volume = "17",
number = "Supplement 4",
pages = "S261-S262",
doi = "10.1016/S0924-977X(07)70358-9"
}

Vučićević, K., Miljković, B., Petronijević, M., Pokrajac, M., Veličković, R.,& Grabnar, I.. (2007). Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 17(Supplement 4), S261-S262.
https://doi.org/10.1016/S0924-977X(07)70358-9

Vučićević K, Miljković B, Petronijević M, Pokrajac M, Veličković R, Grabnar I. Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study. in European Neuropsychopharmacology. 2007;17(Supplement 4):S261-S262.
doi:10.1016/S0924-977X(07)70358-9 .

Vučićević, Katarina, Miljković, Branislava, Petronijević, M., Pokrajac, Milena, Veličković, Ružica, Grabnar, Iztok, "Induction of carbamazepine metabolism during co-treatment with phenobarbitone - a population pharmacokinetic study" in European Neuropsychopharmacology, 17, no. Supplement 4 (2007):S261-S262,
https://doi.org/10.1016/S0924-977X(07)70358-9 . .

TY  - JOUR
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Pokrajac, Milena
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1014
AB  - Antibiotics (AB) and antifungals are large, heterogeneous, and commonly prescribed groups of drugs. Even thou, their use in therapy are considered to be safe, during concomitant use with other drugs the result can be clinically important interaction. Certain classes of AB or antifungal drugs are known to interact with many other drugs, but the interaction potential of them is not uniform among members of the class. Therefore, choosing the appropriate drug allows the possibility to avoid potentially dangerous drug-drug interactions.
AB  - Antibiotici (AB) i antimikotici predstavljaju velike, heterogene i često propisivane grupe lekova. Iako se smatraju za relativno bezbedne lekove, pri istovremenoj primeni sa drugim lekovima mogu da stupe u klinički značajne interakcije. Određene grupe AB i antimikotika su poznate da stupaju u interakcije, ali potencijal za stupanje u interakcije unutar istih klasa lekova je različit, što pruža mogućnost da se odgovarajućim odabirom AB odnosno antimikotika izbegnu potencijalno štetne lek-lek interakcije.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Clinically important interactions of antibiotics and antifungal drugs with other drugs
T1  - Klinički značajne interakcije antibiotika i antimikotika sa drugim lekovima
VL  - 57
IS  - 4-5
SP  - 317
EP  - 331
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1014
ER  - 

@article{
author = "Miljković, Branislava and Vučićević, Katarina and Pokrajac, Milena",
year = "2007",
abstract = "Antibiotics (AB) and antifungals are large, heterogeneous, and commonly prescribed groups of drugs. Even thou, their use in therapy are considered to be safe, during concomitant use with other drugs the result can be clinically important interaction. Certain classes of AB or antifungal drugs are known to interact with many other drugs, but the interaction potential of them is not uniform among members of the class. Therefore, choosing the appropriate drug allows the possibility to avoid potentially dangerous drug-drug interactions., Antibiotici (AB) i antimikotici predstavljaju velike, heterogene i često propisivane grupe lekova. Iako se smatraju za relativno bezbedne lekove, pri istovremenoj primeni sa drugim lekovima mogu da stupe u klinički značajne interakcije. Određene grupe AB i antimikotika su poznate da stupaju u interakcije, ali potencijal za stupanje u interakcije unutar istih klasa lekova je različit, što pruža mogućnost da se odgovarajućim odabirom AB odnosno antimikotika izbegnu potencijalno štetne lek-lek interakcije.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Clinically important interactions of antibiotics and antifungal drugs with other drugs, Klinički značajne interakcije antibiotika i antimikotika sa drugim lekovima",
volume = "57",
number = "4-5",
pages = "317-331",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1014"
}

Miljković, B., Vučićević, K.,& Pokrajac, M.. (2007). Clinically important interactions of antibiotics and antifungal drugs with other drugs. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 57(4-5), 317-331.
https://hdl.handle.net/21.15107/rcub_farfar_1014

Miljković B, Vučićević K, Pokrajac M. Clinically important interactions of antibiotics and antifungal drugs with other drugs. in Arhiv za farmaciju. 2007;57(4-5):317-331.
https://hdl.handle.net/21.15107/rcub_farfar_1014 .

Miljković, Branislava, Vučićević, Katarina, Pokrajac, Milena, "Clinically important interactions of antibiotics and antifungal drugs with other drugs" in Arhiv za farmaciju, 57, no. 4-5 (2007):317-331,
https://hdl.handle.net/21.15107/rcub_farfar_1014 .

TY  - CONF
AU  - Brzaković, Branka
AU  - Pokrajac, Milena
AU  - Miljković, Branislava
AU  - Martinović, Žarko J.
AU  - Veličković, Ružica
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/972
PB  - Springer, Dordrecht
C3  - Pharmacy World & Science
T1  - Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy
VL  - 29
IS  - 5
SP  - 499
EP  - 499
UR  - https://hdl.handle.net/21.15107/rcub_farfar_972
ER  - 

@conference{
author = "Brzaković, Branka and Pokrajac, Milena and Miljković, Branislava and Martinović, Žarko J. and Veličković, Ružica",
year = "2007",
publisher = "Springer, Dordrecht",
journal = "Pharmacy World & Science",
title = "Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy",
volume = "29",
number = "5",
pages = "499-499",
url = "https://hdl.handle.net/21.15107/rcub_farfar_972"
}

Brzaković, B., Pokrajac, M., Miljković, B., Martinović, Ž. J.,& Veličković, R.. (2007). Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy. in Pharmacy World & Science
Springer, Dordrecht., 29(5), 499-499.
https://hdl.handle.net/21.15107/rcub_farfar_972

Brzaković B, Pokrajac M, Miljković B, Martinović ŽJ, Veličković R. Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy. in Pharmacy World & Science. 2007;29(5):499-499.
https://hdl.handle.net/21.15107/rcub_farfar_972 .

Brzaković, Branka, Pokrajac, Milena, Miljković, Branislava, Martinović, Žarko J., Veličković, Ružica, "Correlation between dose and plasma concentrations of lamotrigine in adult patients and children with epilepsy" in Pharmacy World & Science, 29, no. 5 (2007):499-499,
https://hdl.handle.net/21.15107/rcub_farfar_972 .

TY  - JOUR
AU  - Rakić, Anita
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Vučićević, Katarina
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/948
AB  - A selective, sensitive, and simple high-performance liquid chromatographic (HPLC) method was developed for the determination of moclobemide and its two major metabolites, Ro 12-5637 and Ro 12-8095, in human plasma. Sample preparation (0.5 ml of plasma) involved solid-phase extraction (SPE) using Speedisk (R) H2O-Philic DVB columns. Separations were performed on a Waters XTerra (TM) RP18 column (5 mu m, 150 mm x 4.6 mm). The mobile phase consisted of 10 mM KH2PO4 with 1% triethylamine (pH 3.9) and acetonitrile (93:17, v/v), and a flow-rate was 1.2 ml/min. The total run time was 13 min. UV detection was performed at 240 nm. Mean absolute recoveries were >= 90% and the limit of quantification (LOQ) for all analytes was 0.02 mg/l. Calibration curves were linear (r > 0.995) over a wide range of the analyte concentrations in plasma; thus, the method is suitable for different clinical studies when large variations in the drug/metabolites concentrations are observed. During a 5-day assay validation procedure the accuracy and precision were tested and proven (relative errors (RE)  lt = 13%; intra-day coefficient of variation (CV)  lt = 7%; inter-day CV  lt = 13%). Many drugs frequently used in the target patient population were evaluated for potential interference in order method selectivity to be ensured. The assay has been used in a clinical pharmacokinetic study to assess steady-state pharmacokinetics of moclobenide and two metabolites in depressive patients on mono- and combined therapy.
PB  - Elsevier Science BV, Amsterdam
T2  - Journal of Pharmaceutical and Biomedical Analysis
T1  - High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma
VL  - 43
IS  - 4
SP  - 1416
EP  - 1422
DO  - 10.1016/j.jpba.2006.10.032
ER  - 

@article{
author = "Rakić, Anita and Miljković, Branislava and Pokrajac, Milena and Vučićević, Katarina",
year = "2007",
abstract = "A selective, sensitive, and simple high-performance liquid chromatographic (HPLC) method was developed for the determination of moclobemide and its two major metabolites, Ro 12-5637 and Ro 12-8095, in human plasma. Sample preparation (0.5 ml of plasma) involved solid-phase extraction (SPE) using Speedisk (R) H2O-Philic DVB columns. Separations were performed on a Waters XTerra (TM) RP18 column (5 mu m, 150 mm x 4.6 mm). The mobile phase consisted of 10 mM KH2PO4 with 1% triethylamine (pH 3.9) and acetonitrile (93:17, v/v), and a flow-rate was 1.2 ml/min. The total run time was 13 min. UV detection was performed at 240 nm. Mean absolute recoveries were >= 90% and the limit of quantification (LOQ) for all analytes was 0.02 mg/l. Calibration curves were linear (r > 0.995) over a wide range of the analyte concentrations in plasma; thus, the method is suitable for different clinical studies when large variations in the drug/metabolites concentrations are observed. During a 5-day assay validation procedure the accuracy and precision were tested and proven (relative errors (RE)  lt = 13%; intra-day coefficient of variation (CV)  lt = 7%; inter-day CV  lt = 13%). Many drugs frequently used in the target patient population were evaluated for potential interference in order method selectivity to be ensured. The assay has been used in a clinical pharmacokinetic study to assess steady-state pharmacokinetics of moclobenide and two metabolites in depressive patients on mono- and combined therapy.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
title = "High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma",
volume = "43",
number = "4",
pages = "1416-1422",
doi = "10.1016/j.jpba.2006.10.032"
}

Rakić, A., Miljković, B., Pokrajac, M.,& Vučićević, K.. (2007). High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma. in Journal of Pharmaceutical and Biomedical Analysis
Elsevier Science BV, Amsterdam., 43(4), 1416-1422.
https://doi.org/10.1016/j.jpba.2006.10.032

Rakić A, Miljković B, Pokrajac M, Vučićević K. High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma. in Journal of Pharmaceutical and Biomedical Analysis. 2007;43(4):1416-1422.
doi:10.1016/j.jpba.2006.10.032 .

Rakić, Anita, Miljković, Branislava, Pokrajac, Milena, Vučićević, Katarina, "High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma" in Journal of Pharmaceutical and Biomedical Analysis, 43, no. 4 (2007):1416-1422,
https://doi.org/10.1016/j.jpba.2006.10.032 . .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Milijković, Branislava
AU  - Veličković, Ružica
AU  - Pokrajac, Milena
AU  - Mrhar, Ales
AU  - Grabnar, Iztok
PY  - 2007
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/898
AB  - The aim of the present study was to develop a population pharmacokinetic model of carbamazepine from routine therapeutic drug monitoring data. Steady-state carbamazepine plasma concentrations determined by homogenous enzyme immunoassay technique, dosing history including cotherapy, schedule of blood sampling, and patients' demographic characteristics were collected retrospectively from patients' chart histories. A one-compartment model was fitted to the data using nonlinear mixed effects modeling. The influence of weight, age, gender, smoking, allergy, carbamazepine daily dose, and cotherapy on clearance (CL/F) was evaluated. Additionally, bioavailability of controlled-release relative to immediate-release tablets was assessed. Two hundred sixty-five patients (423 concentrations) were used to develop a population pharmacokinetic model. The population estimate of CL/F from the base model was 5.14 L/h with interindividual variability of 50.20%. Patients' gender, age, smoking, allergy, cotherapy with lamotrigine and benzodiazepines had no effect on CUE Patient weight (WT), daily carbamazepine dose (DCBZ), daily dose of phenobarbitone (DPB) and valproic acid (VPA), when its daily dose exceeded 750 mg, significantly influenced CL/F and were included in the final model: CL/F [L/h] = 5.35 (DCBZ [mg/da/kg]/15)(0.591) (1 + 0.414 (DPB [mg/day/kg]/2) (WT [kg]/70)(0.564) 1.18(VPA) where VPA is 1 if dose is greater than 750 mg or 0 otherwise. No difference in bioavailability of carbamazepine between controlled and immediate-release tablets was detected. The model predictions in the validation set had no bias and satisfactory precision. The model can be used for estimation of carbamazepine CL/F in individual patients in the postautoinduction phase and for selection of optimum dosing regimen in routine patient care.
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Therapeutic Drug Monitoring
T1  - Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data
VL  - 29
IS  - 6
SP  - 781
EP  - 788
UR  - https://hdl.handle.net/21.15107/rcub_farfar_898
ER  - 

@article{
author = "Vučićević, Katarina and Milijković, Branislava and Veličković, Ružica and Pokrajac, Milena and Mrhar, Ales and Grabnar, Iztok",
year = "2007",
abstract = "The aim of the present study was to develop a population pharmacokinetic model of carbamazepine from routine therapeutic drug monitoring data. Steady-state carbamazepine plasma concentrations determined by homogenous enzyme immunoassay technique, dosing history including cotherapy, schedule of blood sampling, and patients' demographic characteristics were collected retrospectively from patients' chart histories. A one-compartment model was fitted to the data using nonlinear mixed effects modeling. The influence of weight, age, gender, smoking, allergy, carbamazepine daily dose, and cotherapy on clearance (CL/F) was evaluated. Additionally, bioavailability of controlled-release relative to immediate-release tablets was assessed. Two hundred sixty-five patients (423 concentrations) were used to develop a population pharmacokinetic model. The population estimate of CL/F from the base model was 5.14 L/h with interindividual variability of 50.20%. Patients' gender, age, smoking, allergy, cotherapy with lamotrigine and benzodiazepines had no effect on CUE Patient weight (WT), daily carbamazepine dose (DCBZ), daily dose of phenobarbitone (DPB) and valproic acid (VPA), when its daily dose exceeded 750 mg, significantly influenced CL/F and were included in the final model: CL/F [L/h] = 5.35 (DCBZ [mg/da/kg]/15)(0.591) (1 + 0.414 (DPB [mg/day/kg]/2) (WT [kg]/70)(0.564) 1.18(VPA) where VPA is 1 if dose is greater than 750 mg or 0 otherwise. No difference in bioavailability of carbamazepine between controlled and immediate-release tablets was detected. The model predictions in the validation set had no bias and satisfactory precision. The model can be used for estimation of carbamazepine CL/F in individual patients in the postautoinduction phase and for selection of optimum dosing regimen in routine patient care.",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Therapeutic Drug Monitoring",
title = "Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data",
volume = "29",
number = "6",
pages = "781-788",
url = "https://hdl.handle.net/21.15107/rcub_farfar_898"
}

Vučićević, K., Milijković, B., Veličković, R., Pokrajac, M., Mrhar, A.,& Grabnar, I.. (2007). Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. in Therapeutic Drug Monitoring
Lippincott Williams & Wilkins, Philadelphia., 29(6), 781-788.
https://hdl.handle.net/21.15107/rcub_farfar_898

Vučićević K, Milijković B, Veličković R, Pokrajac M, Mrhar A, Grabnar I. Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. in Therapeutic Drug Monitoring. 2007;29(6):781-788.
https://hdl.handle.net/21.15107/rcub_farfar_898 .

Vučićević, Katarina, Milijković, Branislava, Veličković, Ružica, Pokrajac, Milena, Mrhar, Ales, Grabnar, Iztok, "Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data" in Therapeutic Drug Monitoring, 29, no. 6 (2007):781-788,
https://hdl.handle.net/21.15107/rcub_farfar_898 .

TY  - CONF
AU  - Miljković, Branislava
AU  - Rakić, A.
AU  - Kovačević, Ivan
AU  - Pokrajac, Milena
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/696
PB  - Savez farmaceutskih udruženja Srbije, Beograd
C3  - Arhiv za farmaciju
T1  - The role of pharmacist in monitoring pharmacotherapy safety
T1  - Uloga farmaceuta u praćenju bezbednosti farmakoterapije
VL  - 56
IS  - 5
SP  - 812
EP  - 813
UR  - https://hdl.handle.net/21.15107/rcub_farfar_696
ER  - 

@conference{
author = "Miljković, Branislava and Rakić, A. and Kovačević, Ivan and Pokrajac, Milena",
year = "2006",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "The role of pharmacist in monitoring pharmacotherapy safety, Uloga farmaceuta u praćenju bezbednosti farmakoterapije",
volume = "56",
number = "5",
pages = "812-813",
url = "https://hdl.handle.net/21.15107/rcub_farfar_696"
}

Miljković, B., Rakić, A., Kovačević, I.,& Pokrajac, M.. (2006). The role of pharmacist in monitoring pharmacotherapy safety. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 56(5), 812-813.
https://hdl.handle.net/21.15107/rcub_farfar_696

Miljković B, Rakić A, Kovačević I, Pokrajac M. The role of pharmacist in monitoring pharmacotherapy safety. in Arhiv za farmaciju. 2006;56(5):812-813.
https://hdl.handle.net/21.15107/rcub_farfar_696 .

Miljković, Branislava, Rakić, A., Kovačević, Ivan, Pokrajac, Milena, "The role of pharmacist in monitoring pharmacotherapy safety" in Arhiv za farmaciju, 56, no. 5 (2006):812-813,
https://hdl.handle.net/21.15107/rcub_farfar_696 .

TY  - CONF
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Petronijević, M.
AU  - Pokrajac, Milena
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/703
PB  - Savez farmaceutskih udruženja Srbije, Beograd
C3  - Arhiv za farmaciju
T1  - Clinically significant CYP 450 mediated drug: Drug interactions
T1  - Klinički značajnije CYP 450 posredovane lek - lek interakcije
VL  - 56
IS  - 5
SP  - 810
EP  - 811
UR  - https://hdl.handle.net/21.15107/rcub_farfar_703
ER  - 

@conference{
author = "Vučićević, Katarina and Miljković, Branislava and Petronijević, M. and Pokrajac, Milena",
year = "2006",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Clinically significant CYP 450 mediated drug: Drug interactions, Klinički značajnije CYP 450 posredovane lek - lek interakcije",
volume = "56",
number = "5",
pages = "810-811",
url = "https://hdl.handle.net/21.15107/rcub_farfar_703"
}

Vučićević, K., Miljković, B., Petronijević, M.,& Pokrajac, M.. (2006). Clinically significant CYP 450 mediated drug: Drug interactions. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 56(5), 810-811.
https://hdl.handle.net/21.15107/rcub_farfar_703

Vučićević K, Miljković B, Petronijević M, Pokrajac M. Clinically significant CYP 450 mediated drug: Drug interactions. in Arhiv za farmaciju. 2006;56(5):810-811.
https://hdl.handle.net/21.15107/rcub_farfar_703 .

Vučićević, Katarina, Miljković, Branislava, Petronijević, M., Pokrajac, Milena, "Clinically significant CYP 450 mediated drug: Drug interactions" in Arhiv za farmaciju, 56, no. 5 (2006):810-811,
https://hdl.handle.net/21.15107/rcub_farfar_703 .

TY  - CONF
AU  - Petronijević, M.
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Pokrajac, Milena
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/817
PB  - Savez farmaceutskih udruženja Srbije, Beograd
C3  - Arhiv za farmaciju
T1  - From compliance to concordance: The pharmacist's perspective
T1  - Od compliance do concordance - iz ugla farmaceuta
VL  - 56
IS  - 5
SP  - 840
EP  - 841
UR  - https://hdl.handle.net/21.15107/rcub_farfar_817
ER  - 

@conference{
author = "Petronijević, M. and Miljković, Branislava and Vučićević, Katarina and Pokrajac, Milena",
year = "2006",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "From compliance to concordance: The pharmacist's perspective, Od compliance do concordance - iz ugla farmaceuta",
volume = "56",
number = "5",
pages = "840-841",
url = "https://hdl.handle.net/21.15107/rcub_farfar_817"
}

Petronijević, M., Miljković, B., Vučićević, K.,& Pokrajac, M.. (2006). From compliance to concordance: The pharmacist's perspective. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 56(5), 840-841.
https://hdl.handle.net/21.15107/rcub_farfar_817

Petronijević M, Miljković B, Vučićević K, Pokrajac M. From compliance to concordance: The pharmacist's perspective. in Arhiv za farmaciju. 2006;56(5):840-841.
https://hdl.handle.net/21.15107/rcub_farfar_817 .

Petronijević, M., Miljković, Branislava, Vučićević, Katarina, Pokrajac, Milena, "From compliance to concordance: The pharmacist's perspective" in Arhiv za farmaciju, 56, no. 5 (2006):840-841,
https://hdl.handle.net/21.15107/rcub_farfar_817 .